{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T10:09:47Z","timestamp":1775210987227,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ALK"},{"name":"GSK"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genetech"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Optinose"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.iac.2019.12.006","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T16:07:53Z","timestamp":1578499673000},"page":"295-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Role of Biologics in the Treatment of Nasal Polyps"],"prefix":"10.1016","volume":"40","author":[{"given":"Christine B.","family":"Franzese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.iac.2019.12.006_bib1","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.iac.2019.12.006_bib2","first-page":"S3","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis executive summary","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.iac.2019.12.006_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2019.12.006_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in Chronic Rhinosinusitis","author":"Stevens","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2019.12.006_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1945892418787132","article-title":"Biologics in chronic rhinosinusitis: an update and thoughts for future directions","volume":"32","author":"Smith","year":"2018","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1016\/j.iac.2019.12.006_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.otc.2010.04.003","article-title":"A\u00a0comprehensive review of the adverse effects of systemic corticosteroids","volume":"43","author":"Poetker","year":"2010","journal-title":"Otolaryngol Clin North Am"},{"key":"10.1016\/j.iac.2019.12.006_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1081-1206(10)61928-X","article-title":"Omalizumab and the immune system: an overview of preclinical and clinical data","volume":"89","author":"Johansson","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2019.12.006_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2019.12.006_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"issue":"5","key":"10.1016\/j.iac.2019.12.006_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2019.12.006_bib17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856119300979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856119300979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:43:04Z","timestamp":1760179384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856119300979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0889856119300979"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2019.12.006","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Biologics in the Treatment of Nasal Polyps","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}